Drug Interaction Report
1 potential interaction and/or warning found for the following 2 drugs:
- interferon alfacon-1
- Tysabri (natalizumab)
Interactions between your drugs
interferon alfacon-1 natalizumab
Applies to: interferon alfacon-1, Tysabri (natalizumab)
Using natalizumab together with interferon alfacon-1, or using them sequentially with little to no time in between, may increase the risk of serious and potentially life-threatening infections. Of particular concern is an infection known as progressive multifocal leukoencephalopathy (PML), which is a rare but serious viral infection of the brain that may lead to disability and death. If you are currently being treated or have recently been treated with interferon alfacon-1, you may not be able to use natalizumab, or you may require close monitoring and special tests by your doctor to minimize the risk of infection during treatment. Let your doctor know if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. Also seek immediate medical attention if you experience progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, confusion, or changes in thinking, memory and personality, as these may be early symptoms of PML. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
No alcohol/food interactions were found with the drugs in your list. However, this does not necessarily mean no food interactions exist. Always consult your healthcare provider.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Epclusa
Epclusa treats chronic hepatitis C in adults and children 3+. This once-daily antiviral combines ...
Mavyret
Mavyret (glecaprevir/pibrentasvir) is an oral combination medicine containing fixed doses of two ...
Taltz
Taltz (ixekizumab) is used to treat plaque psoriasis, psoriatic arthritis, and ankylosing ...
Harvoni
Harvoni is used to treat hepatitis C virus (HCV) infections in adults and children aged 3 years and ...
Sovaldi
Sovaldi (sofosbuvir) is used to treat chronic hepatitis C virus (HCV) infection. Includes Sovaldi ...
Vosevi
Vosevi (sofosbuvir,velpatasvir and voxilaprevir) is used to treat chronic hepatitis C. Includes ...
Pegasys
Pegasys is used to treat chronic hepatitis B or C. Learn about side effects, interactions and ...
Zepatier
Zepatier (elbasvir and grazoprevir) is used to treat chronic hepatitis C. Includes Zepatier side ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.